SCHEMBL13872151

SCHEMBL13872151

INc1ccc2sccc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 2/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 1/20 0.45
TP53 P04637 1/20 0.45
NFKB1 P19838 1/20 0.45
NFKB2 Q00653 1/20 0.45
RELA Q04206 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
HTR2C P28335 2/20 0.42
HTR2A P28223 1/20 0.42
DYRK1A Q13627 1/20 0.42
PTPRC P08575 1/20 0.41
PTPN6 P29350 1/20 0.41
PTPN11 Q06124 1/20 0.41
PTPN22 Q9Y2R2 1/20 0.41
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2656510 0.79 CYP2A6 (0.46) CYP2A6MEN1KMT2ANPC1RAB9A
SCHEMBL29472298 0.79 CYP2A6 (0.46) CYP2A6MEN1KMT2ANPC1RAB9A
SCHEMBL15389974 0.79 CYP2A6 (0.50) CYP2A6MEN1KMT2ANPC1RAB9A
Hydrochloric Acid SCHEMBL11180431 0.78 CYP2A6 (0.48) CYP2A6MEN1KMT2ANPC1RAB9A
SCHEMBL10369397 0.75 CYP2A6 (0.46) CYP2A6MEN1KMT2ANPC1RAB9A
SCHEMBL10133289 0.75 CYP2A6 (0.55) CYP2A6MEN1KMT2ANPC1RAB9A
SCHEMBL17740782 0.75 ALDH1A1 (0.55) CYP2A6MEN1KMT2ANPC1RAB9A
SCHEMBL18875992 0.75 CYP2A6 (0.46) CYP2A6MEN1KMT2ANPC1RAB9A
SCHEMBL20419214 0.75 HTR2C (0.46) CYP2A6MEN1KMT2ANPC1RAB9A
SCHEMBL4315507 0.73 MEN1 (0.58) CYP2A6MEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021039961-A1 RING-FUSED PYRAZOLE DERIVATIVE 大日本住友製薬株式会社 2021-03-04 WO disclosed
EP-2215074-B1 ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES US HEALTH (US) 2014-02-19 EP disclosed
EP-2573080-A1 Isoindoline compounds for the treatment of spinal muscular atrophy and other uses The United States of America, as Represented by the Secretary, Department of Health and Human Services (US) 2013-03-27 EP disclosed
WO-2009042907-A1 ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2009-04-02 WO disclosed